Previous 10 | Next 10 |
Immunic to Host MS R&D Day and Participate in Investor Conferences in April Immunic to Host MS R&D Day and Participate in Investor Conferences in April PR Newswire NEW YORK , April 4, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a b...
2024-03-22 15:00:00 ET More on the markets Wall Street Lunch: Fed Not Spooked By Recent Inflation SPY: Don't Fall For The Greed SPY: Assessing Economic Risks And Market Trends (Technical Analysis, Rating Downgrade) Investors sell $66B worth of money market fu...
--News Direct-- Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month, highlighting the disease's impact, development, and the unmet medical n...
--News Direct-- Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with news the company has received a Notice of Allowance from the US Patent and Trademark Office for a new patent application, marking a significant step in the company's intellectual property (IP) strategy. ...
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States PR Newswire – Patent Will Also Cover a Related Method of Production of the Material – – Fourth U.S. Patent Di...
--News Direct-- Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with details of data from the Phase 2 CALLIPER and CALVID-1 trials of vidofludimus calcium the company will present at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2...
2024-03-04 09:30:00 ET March 4, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the AI (artificial intelligence) Tech and Biotech sectors. The newest tech companies are all invo...
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 PR Newswire NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipelin...
2024-02-22 15:38:13 ET Immunic, Inc. (IMUX) Q4 2023 Earnings Conference Call February 22, 2024, 8:00 AM ET Company Participants Jessica Breu - Vice President, Investor Relations and Communications Daniel Vitt - Chief Executive Officer, President and Director Glen...
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on February 22, 2024 – NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Immunic...
News, Short Squeeze, Breakout and More Instantly...
Immunic Inc. Company Name:
IMUX Stock Symbol:
NYSE Market:
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...